stated therein. The sale price was determined through a book building process. The proposed sell-down of the Units is strictly a financing exercise to fund, amongst other things, working capital needs and
profit of 2Q19. However, net profit margin remained at 17% unchanged from previous year despite revenue decrease (given that 2Q19 not included non-recurring items). Most of cost and expenses were
unchanged from previous year despite the decrease of SW income . Non-SW income has more than offset the unfavorable SW income while cost has been under control. Page 3 of 4 Statement of Financial Position as
meaningfully changed yoy. Trade receivable and Trade payable period were slightly decreased while inventory period was unchanged. Leverage ratio has improved as illustrated by Interest Coverage ratio (EBITDA
rating to be enhanced from its stand-alone rating. On a stand-alone basis, TRIS’s view remains unchanged. The Company’s business performance has been relatively strong and stable from its well-diversified
patients. Administrative Expenses Administrative expenses were unchanged yoy. Earnings before interest, taxes and depreciation (“EBITDA”) EBITDA (not included other income) deteriorated by both in term of
future. The new preventive measures will also come with traceability, enhancing the ability to trace back the route of the product. At the current stage, the Company is working on process improvement
its subsidiaries recorded selling expenses of Baht 204 million, quite unchanged YoY. Selling expenses to sales was 15.0%, an increase from 13.4% in Q1/2017 due to lower sales. Q1/2018 Administrative
, respectively. In 4Q’18, the company’s gross margin almost unchanged yoy. For year 2018, gross margin was 31% higher than 30% of year 2017. The improvement in gross margin was contributed by more revenue portion
15% and 14% yoy, respectively. In 2Q’18, the company’s gross margin was 28% of revenue in line with previous year. The unchanged gross margin of 2Q’18 was due to high revenue base of 2Q’17 following